Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Alpelisib | 1 | 72 | 0.32 | 5140.8 | 6091.5 | 1443.3 | -0.495 | 0.843 | 0.844 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.1 | 5660.0 | 6091.5 | 1443.3 | -1.0 | 0.931 | 0.929 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.032 | 5912.0 | 6091.5 | 1443.3 | -1.49 | 0.971 | 0.971 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.01 | 6056.3 | 6091.5 | 1443.3 | -2.0 | 0.994 | 0.994 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.0032 | 5159.8 | 6091.5 | 1443.3 | -2.49 | 0.846 | 0.847 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.001 | 5809.8 | 6091.5 | 1443.3 | -3.0 | 0.955 | 0.954 | 2.077 | BT20 BYL719 0 1 |